Comparative Pharmacology
Head-to-head clinical analysis: FENTANYL 62 versus QOLIANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FENTANYL 62 versus QOLIANA.
FENTANYL-62 vs QOLIANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fentanyl is a synthetic opioid agonist primarily acting on mu-opioid receptors in the central nervous system, leading to analgesia, sedation, and respiratory depression.
QOLIANA (elagolix) is a nonpeptide, orally active gonadotropin-releasing hormone (GnRH) receptor antagonist that competitively binds to GnRH receptors in the pituitary gland, thereby reducing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This leads to decreased ovarian production of estrogen and progesterone, resulting in a hypoestrogenic state.
For analgesia: 50-100 mcg IV/IM every 1-2 hours as needed. For anesthesia: 2-50 mcg/kg IV. For PCA: 10-20 mcg IV with 5-10 min lockout. Transdermal: 12-100 mcg/h patch every 72 hours; start at 25 mcg/h in opioid-naive patients.
Initiate at 5 mg orally once daily, increase as tolerated to 10 mg once daily. Maximum dose 20 mg once daily.
None Documented
None Documented
3–7 hours (terminal elimination half-life; prolonged in elderly, hepatic impairment, or with continuous infusion due to redistribution).
Terminal elimination half-life is 12 hours (range 10–15 hours) in healthy adults; may extend to 18–24 hours in patients with moderate hepatic impairment (Child-Pugh B).
Renal (primarily as metabolites, <10% unchanged; ~75% total metabolites in urine), fecal (~9% total metabolites).
Renal excretion of unchanged drug accounts for approximately 30% of elimination; biliary/fecal excretion accounts for 60% (including metabolites); 10% is metabolized with negligible pulmonary elimination.
Category D/X
Category C
Opioid Agonist
Opioid Agonist